3066905-22-1
3066905-22-1
Chemical Structure
Sofetabart
Synonym(s): LY-4170156 Antibody; MBK-103 Antibody
- CAS No.: 3066905-22-1
- Formula:N/A
- Molecular Weight:(145.23 kDa)
Biological Activity: Sofetabart (LY-4170156 Antibody) is a humanized IgG1 antibody that specifically targets folate receptor α (FRα). Sofetabart can be used to synthesize the antibody-drug conjugate (ADC) Sofetabart mipitecan. Sofetabart is applicable to research related to advanced ovarian cancer, platinum-resistant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, as well as platinum-sensitive ovarian cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sofetabart | 98.00% | Sofetabart (LY-4170156 Antibody) is a humanized IgG1 antibody that specifically targets folate receptor α (FRα). Sofetabart can be used to synthesize the antibody-drug conjugate (ADC) Sofetabart mipitecan. Sofetabart is applicable to research related to advanced ovarian cancer, platinum-resistant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, as well as platinum-sensitive ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. O'Malley D, et al. Update from the phase I study of sofetabart mipitecan (Sofe-M), an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) in advanced ovarian cancer (OC) [abstract]. ESMO Open. 2026;11(Suppl 6):108188.
- [2]. Coyle L. Industry Insights: Bioconjugate innovation gains momentum across partnerships and pivotal trials. Bioconjugate Insights. 2026;1(1):49‑66.
- [3]. Moore KN, et al. Antibody-drug conjugates in gynaecological cancers: opportunities and challenges. Nature reviews. Clinical oncology. 2026 Jun 17. [Content Brief]
- [4]. Ray‑Coquard IL, et al. FRAmework‑01: A two‑part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum‑resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum‑based chemotherapy plus bevacizumab in platinum‑sensitive ovarian cancer (PSOC). J Clin Oncol. 2026;44(16_suppl):TPS5644.
